Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Small Cell Lung Carcinoma 19Ovarian Neoplasms 17Neuroblastoma 15Fallopian Tube Neoplasms 13Neoplasms 6Carcinoma, Ovarian Epithelial 6Ganglioneuroblastoma 5Brain Neoplasms 4Uterine Cervical Neoplasms 3Recurrence 3Neoplasm Metastasis 3Lung Neoplasms 3Glioma 3Central Nervous System Neoplasms 3Sarcoma, Ewing 2Rhabdoid Tumor 2Retinoblastoma 2Medulloblastoma 2Leukemia, Myeloid, Acute 2Wilms Tumor 1Thrombocythemia, Essential 1SCLC, Extensive Stage 1SCLC 1Rhabdomyosarcoma 1Retinal Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Pleuropulmonary blastoma 1Peritoneal Neoplasms 1Pediatric Brain Tumor 1

Interventions

brivaracetam 1Topotecan 1Sirolimus 1Magnetoencephalography 1LY3295668 erbumine 1Ketamine 1Fentanyl 1Cyclophosphamide 1Clinical Laboratory Techniques 1Cannabidiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Epilepsy × Topotecan × 1 year × Clear all
NCT04106219 2026-04-21

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Eli Lilly and Company

Phase 1 Active not recruiting
71 enrolled
CNS

Epilepsy, Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡